Cargando…
Safety and biodistribution of (111)In-amatuximab in patients with mesothelin expressing cancers using Single Photon Emission Computed Tomography-Computed Tomography (SPECT-CT) imaging
Amatuximab is a chimeric high-affinity monoclonal IgG1/k antibody targeting mesothelin that is being developed for treatment of mesothelin-expressing cancers. Considering the ongoing clinical development of amatuximab in these cancers, our objective was to characterize the biodistribution, and dosim...
Autores principales: | Lindenberg, Liza, Thomas, Anish, Adler, Stephen, Mena, Esther, Kurdziel, Karen, Maltzman, Julia, Wallin, Bruce, Hoffman, Kimberly, Pastan, Ira, Paik, Chang Hum, Choyke, Peter, Hassan, Raffit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414206/ https://www.ncbi.nlm.nih.gov/pubmed/25756664 |
Ejemplares similares
-
Amatuximab and novel agents targeting mesothelin for solid tumors
por: Baldo, Paolo, et al.
Publicado: (2017) -
Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine sensitivity and regulates cancer cell stemness in mesothelin-positive pancreatic cancer cells
por: Matsuzawa, Fumihiko, et al.
Publicado: (2021) -
Targeting mesothelin in ovarian cancer
por: Ghafoor, Azam, et al.
Publicado: (2018) -
Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors
por: Fujisaka, Yasuhito, et al.
Publicado: (2014) -
The anti-mesothelin monoclonal antibody amatuximab enhances the anti-tumor effect of gemcitabine against mesothelin-high expressing pancreatic cancer cells in a peritoneal metastasis mouse model
por: Mizukami, Tatsuzo, et al.
Publicado: (2018)